Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4482 Target Snapshot

Serine/threonine-protein kinase PAK 4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,567Compounds
528Assays
9Approved Drugs
2,102.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Serine/threonine-protein kinase PAK 4 shows clinical signal disease relevance led by neoplasm. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O96013. Start with neoplasm, then reuse UniProt O96013 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt O96013 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
neoplasm

Serine/threonine-protein kinase PAK 4 shows clinical signal disease relevance led by neoplasm. 1 linked drug remains visible in the same block.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include PF-03758309. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase PAK 4 as ChEMBL target CHEMBL4482, mapped to UniProt O96013. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase PAK 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4482
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O96013
Serine/threonine-protein kinase PAK 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase PAK 4 is the right protein anchor across sources, using UniProt O96013 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSerine/threonine-protein kinase PAK 4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO96013
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase PAK 4
UniProt AccessionO96013
Component TypeProtein
Sequence Length591 aa

Serine/threonine-protein kinase PAK 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase PAK 4, mapped to UniProt O96013. Sequence length is 591 aa.

Mapped IDO96013
Review nameSerine/threonine-protein kinase PAK 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Serine/threonine-protein kinase PAK 4 shows clinical signal disease relevance led by neoplasm.

Clinical signal Phase I
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugPF-03758309
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include PF-03758309. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
4
Phase III
16
Phase II
17
Phase I
Assay Mix

Activity Type Distribution

IC50337.0
KI1,284.0
EC5079.0
KD402.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3669583 9.03 EC50 0.94 Preclinical
CHEMBL2064631 9.0 EC50 1.0 Preclinical
CHEMBL388978 9.0 IC50 1.0 Preclinical
CHEMBL3128043 8.89 IC50 1.3 Preclinical
CHEMBL3674597 8.8 Ki 1.6 Preclinical
CHEMBL1993661 8.8 Ki 1.585 Preclinical
CHEMBL3674594 8.72 EC50 1.9 Preclinical
CHEMBL3674593 8.72 Ki 1.9 Preclinical
CHEMBL3580667 8.7 Ki 2.0 Preclinical
CHEMBL3669628 8.62 EC50 2.4 Preclinical
Distribution

pChEMBL Value Distribution

57
5.0
132
5.5
165
6.0
86
6.5
96
7.0
100
7.5
47
8.0
18
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

SUNITINIB
CHEMBL535
Approved 2006
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
Assay Landscape

Assay Landscape

528
Total Assays
404
Tested Compounds
3
Assay Types
Binding — 526 assays, 404 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 422 313 6.8
assay format 61 51 6.6
cell-based format 34 17 7.6
subcellular format 9 23 6.2
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —
Functional — 1 assays, 217 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 217 6.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine